

## Biodegradable model for patch in capsule for treatment of peptic ulcers

Luqman Ibni Yaseen, Kalvataka Sudakar.

Suhn	nittad	01 0'	3 2022	
SUDT	mmea:	01-0	)-ZUZZ	

Accepted: 13-03-2022

**ABSTRACT:** Oral dosage is most prominent route for both conventional and novel drug delivery systems. Different kinds of formulations were targeted via oral route for different types of diseases. Thus improve the pharmacokinetic parameters of medications; some of the novel formulations with sustained release and control release were formulated. In the field of pharmaceutical industries / markets, the use of Nano-carriers has shown a much greater effect on behalf of pharmacokinetic parameters. But there is still a big challenge to show gastric residence time for formulations that having short half-life. So many approaches have been adopted by researchers as well as by pharmaceutical industries such as

## Funding Source:- Nil Conflicts of Interest: Nil

## REFERENCES

- [1]. Kumar, M., & Kaushik, D. An Overview On Various Approaches And Recent Patents On Gastroretentive Drug Delivery Systems. Recent Patents on Drug Delivery & Formulation, (2018). doi:10.2174/1872211312666180308 150218
- [2]. Lopes, C. M., Bettencourt, C., Rossi, A., Buttini, F., & Barata, P. Overview on

Mucoadhesive, floating tablets, swelling formulations to improve the gastric residence time for such products. Due to certain disadvantages of such gastro- retentive drug delivery formulations, Patch in capsule drug delivery is the best option to improve the pharmacokinetic parameters as well as the time of gastric residence of such formulations. Patch in capsule is a novel technique designed to increase the duration of gastric residence of drugs and enhance the pharmacokinetic properties of different drugs. Patch in capsule is a formulation of the control release following kinetics in zero order. Keywords:Patch,gastro-intestine,

pharmacokinetics, Half life

gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics, (2016) 510(1), 144–

158. doi:10.1016/j.ijpharm.2016.05.016

- [3]. Wen, H., He, B., Wang, H., Chen, F., Li, P., Cui, M., ... Yang, X. Structure-Based Gastro-Retentive and Controlled-Release Drug Delivery with Novel 3D Printing. (2016). AAPS PharmSciTech, 20(2). doi:10.1208/s12249-018-1237-3
- [4]. Liang, C.-M., Yang, S.-C., Wu, C.-K., Li, Y.-C., Yeh, W.-S., Tai, W.-C., ... Chuah, S.-K. Risk of Recurrent Peptic Ulcer Disease in

DOI: 10.35629/7781-0702328329 | Impact Factor value 7.429 | ISO 9001: 2008 Certified Journal Page 328



Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. Journal of Clinical Medicine, (2019). 8(10), 1722. doi:10.3390/jcm8101722

- [5]. Sarhadi, S., Ganjali, S., Pirro, M., & Sahebkar, A. The role of high-density lipoproteins in antitumor drug delivery. IUBMB Life. (2019). doi:10.1002/iub.2105
- [6]. Lanas, A., & Hirschowitz, B. I. Toxicity of NSAIDs in the stomach and duodenum. European Journal of Gastroenterology & Hepatology, (1999). 11(4), 375– 382. doi:10.1097/00042737-199904000-00003